KR800000144B1 - Process of preparing benzhydrysulphinyl derivatives - Google Patents

Process of preparing benzhydrysulphinyl derivatives Download PDF

Info

Publication number
KR800000144B1
KR800000144B1 KR7602469A KR760002469A KR800000144B1 KR 800000144 B1 KR800000144 B1 KR 800000144B1 KR 7602469 A KR7602469 A KR 7602469A KR 760002469 A KR760002469 A KR 760002469A KR 800000144 B1 KR800000144 B1 KR 800000144B1
Authority
KR
South Korea
Prior art keywords
acid
crl
water
solution
mol
Prior art date
Application number
KR7602469A
Other languages
Korean (ko)
Inventor
루이스라퐁
Original Assignee
파리스-하멜린
소시예떼 아노니메 라보라토이레 엘. 라퐁
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 파리스-하멜린, 소시예떼 아노니메 라보라토이레 엘. 라퐁 filed Critical 파리스-하멜린
Priority to KR7602469A priority Critical patent/KR800000144B1/en
Application granted granted Critical
Publication of KR800000144B1 publication Critical patent/KR800000144B1/en

Links

Landscapes

  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Benzhydrylsulfinyl derivs. and its acid addition salts ≮I; R = CONHOH, C(:NH) NH, N(:NH) NHOH, 2-Δ2-imidazol, n = 1,2,3≉were prepd. by oxidation of formula ≮II; R' = R or group which can be converted to R≉with hydrogen peroxide in the presence of acetic acid. The compds. showed antipyretic, anticonvulsant and anticholinergic activity when tested on rats.

Description

벤즈 히드릴 술피닐 유도체의 제조방법Method for preparing benz hydryl sulfinyl derivative

본 발명은 하기 일반식(I)의 신규 화합물인 벤즈 히드릴 유도체 및 그의 부가염을 제조하는 방법에 관한 것이다.The present invention relates to a benz hydryl derivative, which is a novel compound of general formula (I), and a method for preparing an addition salt thereof.

Figure kpo00001
Figure kpo00001

상기 식에서,Where

n은 1,2 또는 3을 나타내고,n represents 1,2 or 3,

R은

Figure kpo00002
이미 다졸리닐,R is
Figure kpo00002
Already dazolinyl,

또는 NR1R2(여기서 R1은 수소 또는 C1∼C3알킬기이고,Or NR 1 R 2 , wherein R 1 is hydrogen or a C 1 -C 3 alkyl group,

R2는 수소, C1∼C3알킬 또는 CH2-CH2-OH를 나타내거나,R 2 represents hydrogen, C 1 -C 3 alkyl or CH 2 -CH 2 -OH,

R1과 R2는 질소원자와 함께 결합하여 5∼7원소환을 함유하는 복소환을 형성할 수 있으며, 이 복소환은 산소, 질소와 같은 제2의 복소원자에 의해 치환되어도 좋다)를 나타낸다.R 1 and R 2 may be bonded together with a nitrogen atom to form a heterocycle containing a 5 to 7 membered ring, which heterocycle may be substituted by a second heteroatom such as oxygen or nitrogen). .

여기서, 부가염이란 그의 산부가염 및 그의 4급 암모늄염을 의미한다.Here, addition salt means its acid addition salt and its quaternary ammonium salt.

N-복소환기, NR1R2는, 특히, 모르폴리노, 피페리디노, 피롤리디노, 4-메틸피페라지노, 4-(4-클로로페닐)-피페라지노, 4-메틸피페라지노 또는 아제피노가 될 수 있다. 바란직한 기는 모르폴리노 및 피페리디노이다.N-heterocyclic group, NR 1 R 2 is, in particular, morpholino, piperidino, pyrrolidino, 4-methylpiperazino, 4- (4-chlorophenyl) -piperazino, 4-methylpipera Gino or azepine. Preferred groups are morpholino and piperidino.

본 발명에 의해, 상기 일반식(I)의 화합물은 하기 일반식(Ⅱ)의 술피드를 바람직하기로는 초산매질 중에서, 과산화수소로 산화시켜 제조한다.According to the present invention, the compound of general formula (I) is prepared by oxidizing sulfide of general formula (II) with hydrogen peroxide, preferably in an acetic acid medium.

Figure kpo00003
Figure kpo00003

상기식에서,In the above formula,

n은 전술한 바와 같으며,n is as described above,

R'는 R과 같거나 R로 전환될 수 있는 기를 나타낸다.R 'is the same as R or represents a group that can be converted to R.

이 산화반응은 농과산화수소, 즉 110 용량강도 이상의 과산화수소(다시 말하면 과산화수소를 33 중량%이상 함유하는 물)를 사용하여 초산 중에서 행한다. 이산화반응 중 비교적 다량의 대응하는 술포닐 유도체의 생성을 방지하여야만 한다. 실제로, 반응을 1시간 이상 100℃에서 110∼124용량 강도의 과산화수소로 행하는 경우에는 전술한 술포닐 유도체만이 필수적으로 얻어지므로, 술피닐 유도체만을 얻기 위해서는 반응은 50℃ 이하(통상 1시간 이상)에서 행한다. 반응이 발열반응 이므로 초산 중에서 반응물질들을 단지 혼합하고 부가적으로 가열시키지 않아도 37∼45。C의 온도에 도달된다.This oxidation reaction is carried out in acetic acid using concentrated hydrogen peroxide, i.e., hydrogen peroxide of 110 or more capacity strength (in other words, water containing 33% by weight or more of hydrogen peroxide). The production of relatively large amounts of the corresponding sulfonyl derivatives during the oxidation reaction should be prevented. In fact, when the reaction is carried out with hydrogen peroxide having a strength of 110 to 124 volumes at 100 ° C. for at least 1 hour, only the aforementioned sulfonyl derivatives are essentially obtained. Therefore, in order to obtain only sulfinyl derivatives, the reaction is 50 ° C. or lower (usually 1 hour or more). Do it at Since the reaction is exothermic, temperatures of 37-45 ° C are reached without mixing the reactants in acetic acid and heating additionally.

다음 반응식에 따라서, R'가 질소함유기 R(특히 시아노기, 아미노 형성기, 카르복실산기 또는 카르복실레이트기)의 전구물질인 일반식(Ⅳ)의 벤즈히드릴술피닐 화합물을 제조한 다음, 이어서 R기를 생성시키든지 또는 R기를 도입하므로서 가능하다.According to the following reaction formula, benzhydrylsulfinyl compound of formula (IV) wherein R 'is a precursor of nitrogen-containing group R (especially cyano group, amino forming group, carboxylic acid group or carboxylate group) This can be done either by generating R groups or by introducing R groups.

Figure kpo00004
Figure kpo00004

후술하는 실시예 1-A는 이 방법에 의하여 공업적 규모로 화합물을 제조하기 위한 조작조건들을 기술한 것이다.Example 1-A described below describes the operating conditions for preparing the compound on an industrial scale by this method.

과산화수소 및 일반식(Ⅱ)의 슬피드를 거의 화학양론적 양을 사용하는 것이 바람직하다.It is preferable to use an almost stoichiometric amount of hydrogen peroxide and the slip of general formula (II).

후술하는 실시예들은 원료로서 사용되는 술피드 및 일반식(I)의 염기로부터 부가염을 제조하는 방법(예를들면, 유리염기를 무기 또는 유기산과 반응시킴)을 기술한 것이다. 사용되는 산으로서 특히 염산, 브롬화 수소산, 요드화 수소산, 황산, 포름산, 말레산, 푸마르산, 옥살산, 아스코르빈산, 시트르산, 초산, 메탄술폰산, p-톨루엔술폰산, 젖산, 숙신산, 벤조산, 살리실산, 아세틸살리실산, 말산, 타르타르산, 글루타민산 및 아스파라긴산 등을 들 수 있다.The examples described below describe methods for preparing addition salts from sulfides used as raw materials and bases of formula (I) (eg, reacting free bases with inorganic or organic acids). Acids used are in particular hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, formic acid, maleic acid, fumaric acid, oxalic acid, ascorbic acid, citric acid, acetic acid, methanesulfonic acid, p-toluenesulfonic acid, lactic acid, succinic acid, benzoic acid, salicylic acid, acetyl Salicylic acid, malic acid, tartaric acid, glutamic acid and aspartic acid.

본 발명에 의해, 1종 이상의 일반식(I)의 화합물 또는 생리학적으로 허용되는 부형제와 결합한 상기 화합물이 무독성 부가염을 함유하는 것을 특징으로 하는 치료제가 제안되었다.According to the present invention, a therapeutic agent has been proposed wherein the compound in combination with at least one compound of formula (I) or a physiologically acceptable excipient contains a non-toxic addition salt.

하기 제1표는 본 발명에 의해 합성된 화합물들을 나타낸 것이다.Table 1 below shows the compounds synthesized by the present invention.

[표 1]TABLE 1

Figure kpo00005
Figure kpo00005

Figure kpo00006
Figure kpo00006

Note : (a) 염산염Note: (a) Hydrochloride

본 발명의 기타 우수한 효과 및 특징들은 하기에 서술하는 제조 실시예에 의해 명백해질 것이다. 융점은 쾨플러 벤취(K

Figure kpo00007
fler bench)로 측정하였다.Other excellent effects and features of the present invention will become apparent from the production examples described below. Melting point is Köppler Vent
Figure kpo00007
fler bench).

[실시예 1]Example 1

벤즈히드릴술피닐-아세트히드록삼산Benzhydrylsulfinyl-acetic acid

Figure kpo00008
Figure kpo00008

코오드번호 CRL 40,028Code number CRL 40,028

a) 디페닐메탄-티올a) diphenylmethane-thiol

중앙에 기계적 교반기를 설치하고 측구에 적하 깔데기 및 냉각기를 각각 설치한 500ml 삼구 플라스크에 티오우레아 15.2g (0.2mol) 및 탈염수 150ml를 넣었다.15.2 g (0.2 mol) of thiourea and 150 ml of demineralized water were added to a 500 ml three-necked flask equipped with a mechanical stirrer at the center and a dropping funnel and a cooler at the side.

반응혼합물의 온도를 50℃로 올리고 가열을 계속하면서 브로모디페닐메탄 49.4g(0.2mol)을 한꺼번에 모두 첨가하였다.The temperature of the reaction mixture was raised to 50 ° C. and 49.4 g (0.2 mol) of bromodiphenylmethane were added all at once while heating was continued.

약 5분 동안 환류한 후에 맑아진 용액을 20℃로 냉각한 다음, 전술한 온도를 유지하면서, 2.5N-수산화나트륨 200ml를 적가하였다.After refluxing for about 5 minutes, the cleared solution was cooled to 20 ° C. and then 200 ml of 2.5N-sodium hydroxide was added dropwise while maintaining the above temperature.

다음에, 온도를 다시 30분 동안 환류온도로 유지하고, 그 후에, 혼합물이 다시 상온(15∼25℃)으로 될때에, 수용액을 농염산 45ml로서 산성으로 하였다. 상층액 오일을 디에틸에테르 250ml로 추출하고, 유기층을 물 80ml씩 4회 세척한 다음 황산마그네슘상에서 탈수하였다. 조(粗) 디페닐메탄-티올 39g이 얻어졌다. 수율 97.5%The temperature was then maintained at reflux for another 30 minutes, after which the aqueous solution was made acidic with 45 ml of concentrated hydrochloric acid when the mixture was brought to room temperature (15-25 ° C.) again. The supernatant oil was extracted with 250 ml of diethyl ether, and the organic layer was washed four times with 80 ml of water and then dehydrated on magnesium sulfate. 39 g of crude diphenylmethane-thiol were obtained. Yield 97.5%

b) 벤즈히드릴-티오초산b) benzhydryl-thioacetic acid

자기 교반기와 환류냉각기를 장치한 250ml 플라스크에 탈염수 60ml중에 용해시킨 디페닐메탄-티올 10g(0.05mol) 및 수산화나트륨 2g(0.05mol)를 연속적로 도입하였다. 반응물질을 교반하면서 10분 동안접촉시킨 다음 클로로초산 7g (0.075mol), 수산화나트륨 입자 3g (0.075mol) 및 탈염수 60ml를 한꺼번에 모두 첨가하였다.In a 250 ml flask equipped with a magnetic stirrer and a reflux cooler, 10 g (0.05 mol) of diphenylmethane-thiol dissolved in 60 ml of demineralized water and 2 g (0.05 mol) of sodium hydroxide were continuously introduced. The reaction mass was contacted with stirring for 10 minutes, and then 7 g (0.075 mol) of chloroacetic acid, 3 g (0.075 mol) of sodium hydroxide particles, and 60 ml of demineralized water were added all at once.

수용액을 15분 동안 약하게 가온하여 약 50。C로 하고, 에테르 50ml로 세척한 후 경사한 다음 농염산으로 산성으로 하였다. 여과한 후에, 벤즈히드릴-티오초산 : 0.2g을 업었다. 융점 129~130℃, 수율79%The aqueous solution was gently warmed for 15 minutes to about 50 ° C., washed with 50 ml of ether, decanted and acidified with concentrated hydrochloric acid. After filtration, benzhydryl-thioacetic acid: 0.2 g was taken up. Melting Point 129 ~ 130 ℃, Yield 79%

c) 에틸벤즈히드릴-티오아세테이트c) ethylbenzhydryl-thioacetate

반응혼합물 즉, 벤즈히드릴-티오초산 10.2g (0.0395mol), 무수에탄올 100ml 및 황산 2ml 혼합물을 7시간 동안 환류하에 가열시켰다.The reaction mixture, ie 10.2 g (0.0395 mol) of benzhydryl-thioacetic acid, 100 ml of anhydrous ethanol and 2 ml of sulfuric acid was heated under reflux for 7 hours.

가열 종료 후, 에탄올을 진공 중에서 증발시키고, 유상 잔류물을 에틸에테르 100ml에 용해시킨 다음, 유기용액을 물, 탄산나트륨 수용액으로 세척한 다음에, 세척액이 중성의 pH가 될때까지 물로 세척하였다. 황산나트륨상에서 탈수시킨 다음, 용매를 증발시켰더니, 에틸벤즈히드릴티오아세테이트 10.5g이 얻어졌다. 수율 93%.After the completion of the heating, ethanol was evaporated in vacuo, the oily residue was dissolved in 100 ml of ethyl ether, and then the organic solution was washed with water and aqueous sodium carbonate solution, and then washed with water until the washing solution became neutral pH. After dehydration over sodium sulfate, the solvent was evaporated to give 10.5 g of ethylbenzhydrylthioacetate. Yield 93%.

d) 벤즈히드릴-티오아세토히드록삼산d) benzhydryl-thioacetohydroxysamic acid

하기와 같은 세가지 용액을 제조하였다.Three solutions were prepared as follows.

1. 에틸벤즈히드릴-티오아세테이트메탄올 10.8g (0.037mol) 40ml1.Ethylbenzhydryl-thioacetatemethanol 10.8g (0.037mol) 40ml

2. 히드록실아민염산염메탄올 5.25g (0.075mol) 40ml2. Hydroxylamine Hydrochloride Methanol 5.25g (0.075mol) 40ml

3. 수산화칼륨환메탄올 7.5g (0.0134mol) 40ml3. Potassium Hydroxide Methanol 7.5g (0.0134mol) 40ml

이 용액들이 맑아질 때 까지 용액들을 가열하그, 온도가 다시 40℃이하로 떨어질때에, 메탄올 중에 용해시킨 수산화칼륨의 용액을 알코올에 용해시킨 히드록실아민 염산염의 용액에 넣었다. 최종적으로, 약 5∼10℃의 온도에서, 에틸벤즈히드릴-티오아세테이트의 용액을 시간 맞추어 첨가하였다. 반응물질을 10분동안 접촉시킨 후에, 염화나트륨을 여거하고, 얻어지는 맑은 용액을 약 15분 동안 실온으로 유지하였다. 그 다음에, 메탄올을 감압하에서 증발시키고, 잔류 오일을 물 100ml에 용해시킨 다음 수용액을 3N염산으로 산성으로 하였다. 결정화된 히드록삼산을 여거하고, 물로 세척한 다음 건조시켰다. 생성물 9.1g이 얻어졌으머, 수율은 87.5% 이고, 융점은 118∼120℃이었다.The solutions were heated until they became clear and when the temperature dropped below 40 ° C., a solution of potassium hydroxide dissolved in methanol was added to a solution of hydroxylamine hydrochloride dissolved in alcohol. Finally, at a temperature of about 5-10 ° C., a solution of ethylbenzhydryl-thioacetate was added in time. After contacting the reactants for 10 minutes, sodium chloride was filtered off and the resulting clear solution was kept at room temperature for about 15 minutes. Then, methanol was evaporated under reduced pressure, the residual oil was dissolved in 100 ml of water, and the aqueous solution was made acidic with 3N hydrochloric acid. Crystallized hydroxamic acid was filtered off, washed with water and dried. 9.1g of product was obtained, yield was 87.5%, and melting | fusing point was 118-120 degreeC.

e) CRL 40,028e) CRL 40,028

벤즈히드릴-티오아세토히드록삼산 10.4g (0.038mol)을 초산 100ml중의 110 용량 강도의 과산화수소3.8ml (0.038mol)에 의해 2시간 이상 동안 40。C에서 산화시켰다.10.4 g (0.038 mol) of benzhydryl-thioacetohydroxamic acid was oxidized at 40 ° C. for at least 2 hours with 3.8 ml (0.038 mol) of 110 dose strength hydrogen peroxide in 100 ml of acetic acid.

산화 종료 후, 초산을 감압하에서 증발시키고, 잔류오일을 에틸아세테이트 60ml 용해시켰다. 결정화된 생성물을 여거하고, 그 다음에 에틸아세테이트와 이소프로필알코올과의 3 : 2(용적)의 혼합물로 재결정하여 정제하였다. CRL 40,028이 8g 얻어졌다. 융점 159∼160。C 수율73%After the completion of oxidation, acetic acid was evaporated under reduced pressure, and 60 ml of ethyl acetate was dissolved in the residual oil. The crystallized product was filtered off and then purified by recrystallization with a mixture of 3: 2 (volume) of ethyl acetate and isopropyl alcohol. 8g of CRL 40,028 were obtained. Melting point 159-160。C yield 73%

용해도는 물 1ℓ에 1g이하이다.Solubility is less than 1g in 1L of water.

[실시예 1-A]Example 1-A

실시예 1-A는 상기 실시예 1의 목적물인 벤즈히드릴술피닐-아세토히드록삼산은 공업적 규모로 제조하기 위한 방법에 관한 것이다.Example 1-A relates to a method for producing benzhydrylsulfinyl-acetohydroxamic acid, which is the target of Example 1, on an industrial scale.

a) 벤즈히드릴-티오초산의 합성a) Synthesis of Benzhydryl-thioacetic Acid

티오우레아 1.003kg.을 20ℓ용 반응기 내의 48% 농도의 브롬화수소산 5.72ℓ와 물 0.880ℓ에 용해시켰다. 이 혼합물을 60。C까지 가열하고 여기에 벤즈히드롤을 2.024kg을 첨가하였다. 온도를 95℃까지 상승시킨다음, 이 혼합물을 실온, 15∼25℃까지 냉각하였다. 결정물을 여거하고 물로 세척한 다음 다시 이들을 물5.5ℓ에 반죽하고 이것을 수산화나트튬 용액 (d=1.33) 3.5ℓ와 함께 20ℓ 반응기에 넣었다. 이 혼합물을 70。C까지 가열시키고, 물 2.2ℓ에 용해시킨 클로로초산 1,144g을 서서히 첨가하였다. 클로로초산을 첨가한후에 30분 동안 환류시켰다. 이 혼합물을 실온까지 냉각시켜 단리 할 필요가 없는 벤즈히드릴-티오초산을 얻었다.1.003 kg. Of thiourea was dissolved in 5.72 L of hydrobromic acid and 0.880 L of water at 48% concentration in a 20 L reactor. The mixture was heated to 60 ° C. and 2.024 kg benzhydrol was added thereto. The temperature was raised to 95 ° C. and then the mixture was cooled to room temperature, 15-25 ° C. The crystals were filtered off, washed with water and then kneaded again in 5.5 liters of water and placed in a 20 liter reactor with 3.5 liters of sodium hydroxide solution (d = 1.33). The mixture was heated to 70 ° C. and 1,144 g of chloroacetic acid dissolved in 2.2 L of water was added slowly. It was refluxed for 30 minutes after the addition of chloroacetic acid. The mixture was cooled to room temperature to obtain benzhydryl-thioacetic acid that did not need to be isolated.

b) 벤즈히드릴술피닐초산의 합성b) synthesis of benzhydrylsulfinylacetic acid

130용적 농도의 과산화수소 1,430ℓ를 약 30℃의 온도에서 3시간 동안 전술한 반응 혼합물에 첨가시킨다음, 이 뱃취에 물 22ℓ를 넣고, 불용성물질을 여거한 다음 여액을 염산(d=1.18)으로 산성화하였다. 생성물을 여거하고, 물로 세척하그, 다시 물을 첨가하여 반죽한 다음 흡인탈수하였더니, 벤즈 히드릴술피닐초산이 얻어졌다.1430 liters of 130 vol. Of hydrogen peroxide are added to the reaction mixture described above at a temperature of about 30 ° C. for 3 hours, then 22 liters of water is added to this batch, the insolubles are filtered off and the filtrate is acidified with hydrochloric acid (d = 1.18). It was. The product was filtered off, washed with water, kneaded again by adding water, and sucked and dehydrated to obtain benz hydrylsulfinylacetic acid.

c) 메탈벤즈히드릴술피닐아세테이트의 합성c) Synthesis of metal benzhydrylsulfinyl acetate

전술한 산을 물 6ℓ를 채운 20ℓ용 반응기에 넣었다. 여기에 수산화나트륨용액(d=1.33) 1.1ℓ와 중탄 산나트륨 1.84kg을 첨가하였다. 그 다음에 디메틸황산염 2.1ℓ를 첨가하였다. 1시간 후에 결정화를 행하고, 생성물을 여거 하여, 흡인 탈수한 다음 세척하였다. 메틸 벤즈히드릴술피닐아세테이트가 얻어졌다.The acid described above was placed in a 20 liter reactor filled with 6 liters of water. To this was added 1.1 L of sodium hydroxide solution (d = 1.33) and 1.84 kg of sodium bicarbonate. Then 2.1 liters of dimethyl sulfate was added. After 1 hour crystallization was carried out, the product was filtered off, suction dehydrated and washed. Methyl benzhydrylsulfinyl acetate was obtained.

d) 벤즈히드릴술피닐아세토히드록륵삼산의 합성 (CRL 40,028)d) Synthesis of benzhydrylsulfinylacetohydroxamic acid (CRL 40,028)

20ℓ의 반응기에 물8.3ℓ, 수산화나트륨용액(d=1.33)3.3ℓ 및 히드록실아민염산염 1.529kg을 첨가하였다.To a 20 L reactor was added 8.3 L water, 3.3 L sodium hydroxide solution (d = 1.33) and 1.529 kg hydroxylamine hydrochloride.

그 다음에 전술한 에스테르를 첨가하여 이 혼합물을 4시간 동안 교반하였다. 이 용액을 물 17ℓ, 염산(d=1.18) 3ℓ 및 염화메틸렌 4ℓ의 혼합물에 넣고, 혼합물 전체를 교반하였다. 결정물을 여거하고, 다시 물 9ℓ를 첨가하여 반죽을 만든 다음 염화메틸렌 5ℓ를 첨가하였다. 결정들을 30℃의 진공오븐에서 일정한중량이 될때까지 건조시켰다. 생성물을 클로르포름으로 재결정하여 순수한 벤즈히드릴술피닐아세토히드록삼산을 전체수율 53%로 얻었다.Then, the above-mentioned ester was added and the mixture was stirred for 4 hours. The solution was added to a mixture of 17 liters of water, 3 liters of hydrochloric acid (d = 1.18), and 4 liters of methylene chloride, and the whole mixture was stirred. The crystals were filtered off, and 9 l of water was added to make a dough, followed by 5 l of methylene chloride. The crystals were dried in a vacuum oven at 30 ° C. until constant weight. The product was recrystallized from chloroform to give pure benzhydrylsulfinylacetohydroxysamic acid in 53% overall yield.

융점 158∼160℃Melting Point 158-160 ℃

[실시예 2]Example 2

벤즈히드릴 술피닐아세트아미독심 염산염Benzhydryl sulfinylacetamidoxim hydrochloride

(C6H5)2CH-SO-CH2-C (=NH)NHOH·HCl(C 6 H 5 ) 2 CH-SO-CH 2 -C (= NH) NHOHHCl

코오드번호 CRL 40,048Code number CRL 40,048

a) 벤즈히드릴 -티오아세트니트릴a) benzhydryl-thioacetnitrile

자기 교반기가 설치된 250ml플라스크에 디페닐메탄-티올 20g (0.1ml), 무수에탄올 50ml 및 1N 수산화나트륨 용액(0.1mol) 100ml를 도입하였다.Into a 250 ml flask equipped with a magnetic stirrer, 20 g (0.1 ml) of diphenylmethane-thiol, 50 ml of anhydrous ethanol and 100 ml of 1N sodium hydroxide solution (0.1 mol) were introduced.

상온에서 15분 동안 접촉반응을 시킨 후에, 여기에 클로로아세트니트릴 6.91ml (0.11mol)을 적가한 다음 반응물질들을 다시 30분 동안 접촉시켰다. 반응 종료시에, 에탄올을 감압하에서 증발시키고, 그 다음에 수불용정 니트릴을 에틸아세테이트 150ml로 추출하고, 유기층을 물 50ml로 3회 세척한 다음 황산마그네슘상에서 탈수시켰다. 용매를 증발시킨 후에, 잔류하는 오일을 소량의 이소프로판올에 용해시켜, 벤즈히드릴-티오아세토니트릴 13.3g을 분리시켰다. 융점 77∼78。C. 수율 55.6%After 15 minutes of contact reaction at room temperature, 6.91 ml (0.11 mol) of chloroacenitrile was added dropwise thereto, and the reactants were contacted again for 30 minutes. At the end of the reaction, ethanol was evaporated under reduced pressure, then the water insoluble nitrile was extracted with 150 ml of ethyl acetate, the organic layer was washed three times with 50 ml of water and then dehydrated on magnesium sulfate. After evaporation of the solvent, the remaining oil was dissolved in a small amount of isopropanol to separate 13.3 g of benzhydryl-thioacetonitrile. Melting Point 77 ~ 78。C. Yield 55.6%

b) 벤즈히드릴-티오아세트아미독심 염산염b) benzhydryl-thioacetamidoxim hydrochloride

자기 교반기 및 냉각기가 장치된 250ml 단구 플라스크에 중탄산칼륨 ng(0.11mol), 히드록실아민염산염 7.65g(0.11ml) 및 탈염수 50ml를 첨가하였다.To a 250 ml single-necked flask, equipped with a magnetic stirrer and a cooler, ng (0.11 mol) of potassium bicarbonate, 7.65 g (0.11 ml) of hydroxylamine hydrochloride and 50 ml of demineralized water were added.

이산화탄소의 방출 때문에 일어나는 비등이 종료할 때에, 부탄올 200ml중에 용해시킨 벤즈히드릴-티오아세토니트릴 13.3g (0.556mol)을 한꺼번에 모두 첨가하고, 그 다음에 반응혼합물의 온도를 3시간 이상동안 물-부탄올 공비 혼합물의 환류온도로 상승시켰다. 반응 종료시에 용매를 감압하에서 증발시키고, 잔류하는 오일을 에틸아세테이트 150ml에 용해시키고, 유기용액을 물 50ml로 2회 세척한 다음 황산마그네슘상에서 탈수시켰다. 황산마그네슘을 여거한 후에 에테르중에 용해시킨 염화수소의 용액을 첨가하여 아미독심염산을 석출시켰더니 벤즈히드릴-티오아세트아미독심염산염 15.3g가 얻어졌으며, 그의 염기는 암모니아로 유리되었으며, 융점이 112℃이었고, 수율은 89%이었다.At the end of boiling due to the release of carbon dioxide, 13.3 g (0.556 mol) of benzhydryl-thioacetonitrile dissolved in 200 ml of butanol were added all at once, and then the temperature of the reaction mixture was adjusted to water-butanol for at least 3 hours. It was raised to the reflux temperature of the azeotropic mixture. At the end of the reaction, the solvent was evaporated under reduced pressure, and the remaining oil was dissolved in 150 ml of ethyl acetate, the organic solution was washed twice with 50 ml of water and then dehydrated on magnesium sulfate. After filtration of magnesium sulfate, amidoxime hydrochloride was precipitated by adding a solution of hydrogen chloride dissolved in ether to give 15.3 g of benzhydryl-thioacetamidoxin hydrochloride, the base of which was liberated with ammonia and had a melting point of 112 DEG C. , The yield was 89%.

c) CRL 40,048c) CRL 40,048

벤즈히드릴-티오아세트아미독심염산염 15.4g (0.05mol)을 순수한 빙초산 120ml 중에 용해시킨 110 용량 강도의 과산화수소(0.05ml) 5ml로 45℃에서 1시간 동안 산화시켰다. 산화 종료시에, 초산을 감압하에서 증발시키고, 잔류하는 오일을 탈염수 300ml에 용해시키고, 목탄을 통해 수용액을 여거한 후에 암모니아로 알칼리성으로 하였다. 143。C에서 용융하는 결정형 아미독심을 여거하고, 건조시키고, 그 다음에 아세톤 100ml에 용해시킨 다음 에테르 중에 용해시킨 염화수소의 용액을 첨가하여 염산염을 석출시켜 150。C 근방에서 분해하는 CRL 40,048을 11.5g얻었다. 수율 71%.15.4 g (0.05 mol) of benzhydryl-thioacetamidoxime hydrochloride was oxidized at 45 ° C. for 5 hours with 5 ml of 110 volume strength hydrogen peroxide (0.05 ml) dissolved in 120 ml of pure glacial acetic acid. At the end of oxidation, acetic acid was evaporated under reduced pressure, and the remaining oil was dissolved in 300 ml of demineralized water, and the aqueous solution was filtered off through charcoal and made alkaline with ammonia. Crystalline amidoxime, which melts at 143 ° C, is filtered, dried, and then dissolved in 100 ml of acetone, followed by the addition of a solution of hydrogen chloride dissolved in ether to precipitate hydrochloride, decomposing CRL 40,048 that decomposes at around 150 ° C to 11.5. g got. Yield 71%.

무기염소의 측정 [불하르드법 (Volhard method)]Measurement of inorganic chlorine [Volhard method]

계산치 : 10.92%실측치 : 11.17%용해도는 물 1ℓ에 100g이다.Calculated value: 10.92% Found: 11.17% Solubility is 100 g per 1 liter of water.

[실시예 3]Example 3

2-(2-벤즈히드릴술피닐-에틸)-△2-이미다졸린염산염2- (2-benzhydrylsulfinyl-ethyl) -Δ 2 -imidazoline hydrochloride

Figure kpo00009
Figure kpo00009

코오드 번호 CRL 40,066Code number CRL 40,066

a) 벤즈히드릴-티오프로피온이미노에틸에스테르 염산염a) benzhydryl-thiopropioniminoethylester hydrochloride

3-클로로프로피온니트릴 9.2ml (0.2mol)를 에탄올 75ml 및 1N NaOH 110ml중에 용해시킨 벤즈히드릴티올(0.1mol) 20g의 교반용액에 냉각상태에서 첨가하였다. 이 혼합물을 30℃에서 1시간 동안 교반하고 그 다음에 에테르로 추출하고, 추출물을 물로 세척하여 발수시킨 다음 여과하였다. 이 여액에 에탄올10ml를 첨가하고, 이 혼합물을 염화수소 가스로 포화시켜 반응물질들을 48시간 동안 접촉반응시켰다. 또 에테르 100ml를 첨가하고, 혼합물을 여과해서 생성물 23g을 얻었다. 융점 70∼75。C.9.2 ml (0.2 mol) of 3-chloropropionitrile was added to a stirring solution of 20 g of benzhydrylthiol (0.1 mol) dissolved in 75 ml of ethanol and 110 ml of 1N NaOH while cooling. The mixture was stirred at 30 ° C. for 1 h and then extracted with ether, the extract was washed with water, water repelled and filtered. 10 ml of ethanol was added to the filtrate, and the mixture was saturated with hydrogen chloride gas to react the reactants for 48 hours. Further, 100 ml of ether was added, and the mixture was filtered to obtain 23 g of a product. Melting Point 70 ~ 75。C.

b) 2-(2-벤즈히드릴-티오에틸)-△2-이미다졸린염산염b) 2- (2-benzhydryl-thioethyl) -Δ 2 -imidazoline hydrochloride

에탄올 100ml 중에 용해시킨 전술한 이미노에스테르의 염산염(0.046mol) 15.5g 및 에틸렌디아민 3.5ml의 용액을 2시간 동안 환류하에 가열시켰다. 진공 중에서 건조시까지 증발시키고, 농염산 1∼2적을 적가하여 물에 용해시킨 다음 에테르로 세척하였다. 농수산화나트륨으로 염기를 침전시키고, 여거한 다음에 물로 세척하였다. 생성물 11g이 얻어졌다. 수율 81%, 융점 102∼103℃A solution of 15.5 g of the hydrochloride (0.046 mol) of the aforementioned iminoester and 3.5 ml of ethylenediamine dissolved in 100 ml of ethanol was heated under reflux for 2 hours. Evaporate to dryness in vacuo, add 1-2 drops of concentrated hydrochloric acid dropwise, dissolve in water and wash with ether. The base was precipitated with sodium hydroxide, filtered off and washed with water. 11 g of product was obtained. Yield 81%, Melting Point 102-103 ° C

c) CRL 40,066c) CRL 40,066

초산 35ml중에 용해시킨 2-(2-벤즈히드릴-티오에틸)-△2-이미다졸린염산염(0.035ml) 11.6g을 50℃에서 1시간 이상 동안 110용량 강도의 과산화 수소 3.5ml로 산화시켰다. 이 혼합물을 진공 중에서 건조시까지 증발시키고, 잔류물을 아세톤에 용해시킨 다음 여거하었다. 생싱물을 이소프로판올로부터 재결정하였다. CRL 40,066이 전체수율 40%로 얻어졌다. 이것은 162∼164℃에서 분해하며 용융하는 백색분말이다.11.6 g of 2- (2-benzhydryl-thioethyl) -Δ 2 -imidazoline hydrochloride (0.035 ml) dissolved in 35 ml of acetic acid was oxidized to 3.5 ml of 110 vol. . The mixture was evaporated to dryness in vacuo and the residue was dissolved in acetone and then filtered. Fresh water was recrystallized from isopropanol. CRL 40,066 was obtained with a total yield of 40%. It is a white powder that decomposes and melts at 162 to 164 ° C.

[실시예 4]Example 4

N-[2-(벤즈히드릴술피닐)-에틸]-모르폴린염산염N- [2- (benzhydrylsulfinyl) -ethyl] -morpholine hydrochloride

Figure kpo00010
Figure kpo00010

코오드 번호 CRL 40,221Code number CRL 40,221

a) N-(2-벤즈히드릴-티오)-에틸]-모르폴린염산염a) N- (2-benzhydryl-thio) -ethyl] -morpholine hydrochloride

자기 교반기, 적하깔데기 및 냉각기가 설치된 500ml 삼구 플라스크에 티오우레아(0,1mol) 7.6g과 탈염수 100ml를 도입하고, 이 혼합물을 50。C로 가열한 다음 여기에 클로로디페닐메탄(18ml, 0.lmol) 20.25g을 한꺼번에 모두 첨가하였다. 이 용액이 맑아질 때 까지 이 용액을 환류시키고, 그 다음에 20。C까지 냉각하고, 여기에 2.5N 수산화나트륨 200ml를 적가하었다.Into a 500 ml three-necked flask equipped with a magnetic stirrer, a dropping funnel and a cooler, 7.6 g of thiourea (0,1 mol) and 100 ml of demineralized water were introduced, and the mixture was heated to 50 ° C., followed by chlorodiphenylmethane (18 ml, 0. lmol) 20.25 g were added all at once. The solution was refluxed until the solution became clear, then cooled to 20 ° C., and 200 ml of 2.5N sodium hydroxide was added dropwise thereto.

생성되는 용액(형성된 나트륨벤즈히드릴티오레이트를 함유)을 그 다음에 1시간 동안 환류시키고 다시 50℃로 한 다음에 물 80ml중에 용해시킨 2-클로로에틸-모르폴린염산염 (0.1mol) 18.6g의 용액을 적가하였다. 반응 혼합물의 온도를 2시간 이상동안 그의 환류온도로 상승시켰다.18.6 g of 2-chloroethyl-morpholine hydrochloride (0.1 mol) dissolved in the resulting solution (containing the formed sodium benzhydrylthiolate) was then refluxed for 1 hour and brought back to 50 ° C. in 80 ml of water. The solution was added dropwise. The temperature of the reaction mixture was raised to its reflux temperature for at least 2 hours.

혼합물을 냉각하고, 형성된 오일을 에테르로 추출하고, 그 다음에 이 에테르 용액을 1N 염산 70ml로 3회 추출하였다. 목적하는 생성물이 산매질 중의 물로부터 석출된다. 이것을 여거한 다음 이소프로판올로 재결정하였더니 N-[2-(벤즈히드릴-티오)-에틸]-모르폴린히드로클로라이드가 얻어졌다. 융점 176。C클로로디페닐메탄에 대한 수율 76%The mixture was cooled and the oil formed was extracted with ether, then this ether solution was extracted three times with 70 ml of 1N hydrochloric acid. The desired product is precipitated from water in the acid medium. This was filtered off and recrystallized from isopropanol to give N- [2- (benzhydryl-thio) -ethyl] -morpholine hydrochloride. Melting point 176。 76% yield for Cchlorodiphenylmethane

b) CRL 40,221b) CRL 40,221

순수한 초산 70ml중에 용해시킨 상기에서 얻은 염산염(0.0711mol) 24.8g을 125용량 강도의 과산화수소6.4ml로 산화하였다. 반응을 1.5시간 이상동안 40。C에서 행하였다. 마음에 초산을 진공 중에서 증발시키고, 잔류오일을 에테르 중에 용해시키고, 아세톤을 첨가하여 CRL 40,221을 결정시켰더니 생성물 18.9g이 얻어졌다. 융점 166∼168℃.24.8 g of the hydrochloride (0.0711 mol) obtained above dissolved in 70 ml of pure acetic acid was oxidized to 6.4 ml of hydrogen peroxide of 125 volume strength. The reaction was carried out at 40 ° C. for at least 1.5 hours. Acetic acid was evaporated in vacuo to the heart, the residual oil was dissolved in ether, and acetone was added to determine CRL 40,221 to give 18.9 g of product. Melting point 166-168 degreeC.

전체수율 52%52% overall yield

염소측정 (볼하르드법 )Chlorine measurement (Bolhard method)

이론치 : 0.7%Theory: 0.7%

측정치 : 0.7%Measured value: 0.7%

[실시예 5]Example 5

N-[2-(벤즈히드릴술피닐)-에틸]-피페리딘염산염N- [2- (benzhydrylsulfinyl) -ethyl] -piperidine hydrochloride

Figure kpo00011
Figure kpo00011

코오드번호 CRL 40,222Code number CRL 40,222

실시예 4에 기술한 방법을 행하여, N-[2-(벤즈히드릴-티오)-에틸]-피페리딘 염산염(융점 174∼176℃)를 얻었다. 이황화물을 과산화수소로 산화시켜 CRL 40,222를 얻었다. 융점 206∼210。C(분해).The method described in Example 4 was carried out to obtain N- [2- (benzhydryl-thio) -ethyl] -piperidine hydrochloride (melting point 174 to 176 ° C). Disulfide was oxidized with hydrogen peroxide to give CRL 40,222. Melting point 206-210 ° C. (decomposition).

전체수율 : 약 50%Total yield: about 50%

염소측정 (볼하르로법 )Chlorine Measurement (Bolharro Method)

이론치 : 9.75%Theoretic value: 9.75%

실측치 : 9.8%Found: 9.8%

[실시예 6]Example 6

3-(벤즈히드릴술피닐)-프로피오노히드록삼산3- (benzhydrylsulfinyl) -propionohydroxysamic acid

Figure kpo00012
Figure kpo00012

코오드번호 CRL 40,260Code number CRL 40,260

a) 메틸 3-(벤즈히드릴티오)-프로피오네이트a) methyl 3- (benzhydrylthio) -propionate

나트륨벤즈히드릴-티오레이트 0.1mol의 용액을 강한 알칼리성매질 중에서 제조하였다(실시예 4a)에서 기술한 바와 같이 제조하였다). 나트륨 [3-클로로프로피오네이트 3-클로로프로피온산 0.15mol(16.3g)과 탄산나트륨 0.075mol(7.6g)을 물에 용해시켜 얻음]을 약 60℃의 온도에서 상기의 용액에 첨가하였다. 그후에, 이 온도를 비점까기 상승시키고, 이 혼합물을 약 반시간 동안 환류시킨 다음 냉각하고, 목탄으로 여과하고, 농염산으로 산성화하여 3-(벤즈히드릴-티오)-프로피산 16.0g이 석출되었다. 융점 88∼90。C. 클로로디페닐메탄에 대한 수율 59%.A solution of 0.1 mol of sodium benzhydryl-thiolate was prepared in a strong alkaline medium (prepared as described in Example 4a). Sodium [obtained by dissolving 0.15 mol (16.3 g) and 0.075 mol (7.6 g) of sodium carbonate in 3-chloropropionate 3-chloropropionic acid in water] was added to the above solution at a temperature of about 60 ° C. Thereafter, the temperature was raised to boiling point, the mixture was refluxed for about half an hour, cooled, filtered over charcoal, acidified with concentrated hydrochloric acid, and 16.0 g of 3- (benzhydryl-thio) -propanoic acid was precipitated. . Melting Point 88 ~ 90。C. Yield 59% for chlorodiphenylmethane.

그 다음에 상응하는 메틸에스테르를 전술한 산(0.059mol) 16g을 1,2-디클로로에탄40ml에 용해시키고, 여기에 메탄올 10ml 및 농 H2SO40.1ml를 첨가하여 제조하였다. 이 혼합물 전체를 약 5시간 동안 환류온도로 가열시키고 냉각하고, 경사하여 수용액층을 버리고, 유기층을 중탄산나트륨 포화수용액으로 세척하고, 그 다음에 세척수가 중성 pH를 가질때까지 물로 세척하였다. 황산마그네슘상에서 탈수시킨 후에, 용매를 발증시켜 에스테르(맑은 황색오일) 15.7g(0.055mol)을 얻었다.The corresponding methyl ester was then prepared by dissolving 16 g of the aforementioned acid (0.059 mol) in 40 ml of 1,2-dichloroethane and adding 10 ml of methanol and 0.1 ml of concentrated H 2 SO 4 to it. The entire mixture was heated to reflux for about 5 hours, cooled, tilted to discard the aqueous layer, and the organic layer was washed with saturated aqueous sodium bicarbonate solution and then with water until the wash water had a neutral pH. After dehydration on magnesium sulfate, the solvent was evaporated to give 15.7 g (0.055 mol) of ester (clear yellow oil).

산에 대한 수율 93%. 클로로디페닐메탄에 대한 수율 55%.93% yield for acid. Yield 55% for chlorodiphenylmethane.

b) 3-(벤즈하이드릴-티오)-프로피오노히드록삼산b) 3- (benzhydryl-thio) -propionohydroxysamic acid

메탄올 50ml중에 용해시킨 전술한 에스테르 0.055mol(15.7g)을 히드록실아민염기 0.15mol의 용액[히드록실아민 염산염 0.15mol(10.4g)을 나트륨메틸레이트 0.15mol로 중화시켜 제조함]에 첨가하였다. 이 혼합물 전체를 48시간 동안 실온(15∼25。C)에 방치한 다음, 염화나트륨을 여거하고, 메탄올을 증발시키고, 잔류물을 알칼리 수용액으로 용해시켜 이 용액을 목탄으로 여과하고, 이 여액을 농염산으로 산성화하여 목적하는 히드록삼산 7.6g을 단리시켰다. 융점 106∼108。C. 에스테르에 과한 수율 48%.0.055 mol (15.7 g) of the ester described above dissolved in 50 ml of methanol was added to a solution of 0.15 mol of hydroxylamine base (prepared by neutralizing 0.15 mol (10.4 g) of hydroxylamine hydrochloride with 0.15 mol of sodium methylate). The whole mixture is allowed to stand at room temperature (15-25 ° C.) for 48 hours, then sodium chloride is filtered off, methanol is evaporated, the residue is dissolved in an aqueous alkali solution and the solution is filtered over charcoal and the filtrate is concentrated. Acidification with hydrochloric acid isolated 7.6 g of the desired hydroxamic acid. Melting Point 106 ~ 108。C. Yield 48% over ester.

c) CRL 40,260c) CRL 40,260

무수초산 27ml중에 용해시킨 전술한 히드록삼산 0.0264mol(7.6g)을 124용량 강도의 과산화수소 2.4ml로 반응시켰다. 이 혼합물을 1.5시간 동안 40∼45℃에서 방치하고, 초산을 증발시키고, 잔류물을 에틸 아세테이트 50ml에 용해시켜, CRL 40,260을 결정시켰다. 이것을 이소프로판올로 재결정하여 생성물 7.1g을 얻었다. 융점 159∼160℃. 산화로부터의 수율 88%. 전체수율 23.5%.0.0264 mol (7.6 g) of hydroxamic acid described above dissolved in 27 ml of acetic anhydride was reacted with 2.4 ml of hydrogen peroxide with 124 volume strength. This mixture was left for 1.5 h at 40-45 ° C., acetic acid was evaporated and the residue was dissolved in 50 ml of ethyl acetate to determine CRL 40,260. This was recrystallized from isopropanol to give 7.1 g of product. Melting point 159-160 degreeC. Yield 88% from oxidation. Overall yield 23.5%.

[실시예 7]Example 7

3-(벤즈히드릴술피닐)-프로피온아미독심염산염3- (benzhydrylsulfinyl) -propionamidoxime hydrochloride

코오드번호 CRL 40,261Code number CRL 40,261

a) 3-(벤즈히드릴티오)-프로피온니트릴a) 3- (benzhydrylthio) -propionnitrile

나트륨벤즈히드릴-티올레이트(비교실시예 4a) 0.1ml 용액을 제조하고, 그 다음에 β-클로로프로피온니트릴 9.1(0.115mol)를 60∼70℃에서 첨가하었다. 그 다음에 이 혼합물을 환류하에 반시간 동안 가열시킨 다음 냉각시키고, 오일을 에테르로 추출하여 이 에테르 용액을 물로 세척하고 다음에 건조시켰다. 용매를 증발시킨 후에, 니트릴(맑은 녹색오일) 24.5g을 얻었다. 수율 97%.A 0.1 ml solution of sodium benzhydryl-thioleate (Comparative Example 4a) was prepared, and then β-chloropropionnitrile 9.1 (0.115 mol) was added at 60-70 ° C. The mixture was then heated to reflux for half an hour and then cooled, the oil was extracted with ether, the ether solution was washed with water and then dried. After evaporating the solvent, 24.5 g of nitrile (clear green oil) was obtained. Yield 97%.

b) 3-(벤즈히드릴-티오)-프로피온아미독심염산염b) 3- (benzhydryl-thio) -propionamidoxyl hydrochloride

전술한 니트릴 24.5g을 1-부탄을 약 100ml에 용해시켰다. 물 50ml에 용해시킨 히드록실아민염기 0.25mol의 용액[히드록실아민염산염17.4g을 중탄산나트륨21g으로 중화시켜 얻음]을 전술한 용액에 첨가하였다. 이 혼합물 전체를 부탄올-물(2:1) 공비 혼합물의 환류온도에서 가열시키고, 한편으로 적어도 4시간 이상 동안 맹렬히 흔들어 주었다. 그 다음에 냉각하고, 부탄을을 증발시키고, 잔류물을 중성 조건하에서 물로 용해시켜 3-(벤즈히드릴-티오)-프로피온아미독심을 석출시켰더니 염기 19.1g(알코올중에 가용성인 백색분발, 융점 106∼10。C)을 얻었다. 상응하는 염산염을 pH가 산이 될때까지 수 중에 현탁시킨 염기의 현탁액에 염산을 첨가하여 제조하고, 뜨거운 매질 중에 가용성인 염산염을 산용액을 냉각시켜 결정화한다. 이와 같이하여, 3-(벤즈히드릴-티오)-프로피온아미독심염산염 18.4g을 얻었다. 융점 186∼188℃. 전체수율 57%. '24.5 g of the nitrile described above was dissolved in about 100 ml of 1-butane. A solution of 0.25 mol of hydroxylamine base dissolved in 50 ml of water (obtained by neutralizing 17.4 g of hydroxylamine hydrochloride with 21 g of sodium bicarbonate) was added to the solution described above. The entire mixture was heated at the reflux temperature of the butanol-water (2: 1) azeotropic mixture and, on the other hand, was vigorously shaken for at least 4 hours. It was then cooled, butane was evaporated and the residue dissolved in water under neutral conditions to precipitate 3- (benzhydryl-thio) -propionamidoxime which gave 19.1 g of a white powder, soluble in alcohol, melting point 106 -10 ° C) was obtained. The corresponding hydrochloride is prepared by adding hydrochloric acid to a suspension of base suspended in water until the pH is acid, and the soluble hydrochloride in hot medium is crystallized by cooling the acid solution. Thus, 18.4 g of 3- (benzhydryl-thio) -propionamidoxime hydrochloride were obtained. Melting point 186-188 degreeC. Overall yield 57%. '

c) CRL 40,261c) CRL 40,261

CH3COOH 60ml 중에 용해시킨 전술한 염산염 18.4g(0.057mol)을 124용량 강도의 과산화수소 5.2ml로 40∼45。C의 온도에서 1.5시간 동안 반응시켰다. 초산을 증발시키고, 자류물을 에틸아세테이트에 용해시켜, CRL 40,261을 결정화하였다. 이것을 물로 재결정하여 생성물 17.3g을 분리하였다. 융점 164∼166℃. 전체수율 51%.18.4 g (0.057 mol) of the aforementioned hydrochloride dissolved in 60 ml of CH 3 COOH was reacted with 5.2 ml of 124 volume strength hydrogen peroxide at a temperature of 40-45 ° C. for 1.5 hours. Acetic acid was evaporated and the lysate was dissolved in ethyl acetate to crystallize CRL 40,261. It was recrystallized from water to separate 17.3 g of product. Melting point 164-166 degreeC. Overall yield 51%.

[실시예 8]Example 8

4-(벤즈히드릴술피닐)-부티르아미독심염산염4- (benzhydrylsulfinyl) -butyramidoxime hydrochloride

코오드번호 CRL 40,277Code number CRL 40,277

실시예 7에 기술한 방법을 사용하여, 다음과 같은 화합물을 연속 얻었다.Using the method described in Example 7, the following compounds were obtained continuously.

4-(벤즈히드릴-티오)-부티로니트릴, 맑은 오일형,4- (benzhydryl-thio) -butyronitrile, clear oil type,

4-(벤즈히드릴-티오)-부티르아미독심(융점 78∼80℃),4- (benzhydryl-thio) -butyramidoxin (melting point 78-80 ° C.),

상응하는 염산염(융점 132∼133℃) 및 융점 200∼204℃(분해).Corresponding hydrochloride (melting point 132-133 ° C.) and melting point 200-204 ° C. (decomposition).

[실시예 9]Example 9

4-(벤즈히드릴술피닐)-부티로히드록삼산4- (benzhydrylsulfinyl) -butyrohydroxysamic acid

코오드번호 CRL 40,278Code number CRL 40,278

실시예 6에 기술한 방법을 사용하여 다음과 같은 화합물들을 연속적으로 얻었다.Using the method described in Example 6, the following compounds were successively obtained.

4-(벤즈히드릴-타오)-부티르산(융점 91∼92℃).4- (benzhydryl-tao) -butyric acid (melting point 91-92 degreeC).

에틸 4-(벤즈히드릴-티오)-부티레이트, 오일형,Ethyl 4- (benzhydryl-thio) -butyrate, oily,

4-(벤즈히드릴-티오)-부티르히드록삼산(융점 110℃) 및 CRL 40,278, 융점 143℃.4- (benzhydryl-thio) -butyrhydroxamic acid (melting point 110 ° C) and CRL 40,278, melting point 143 ° C.

약리시험을 행한 결과를 아래에 요약한다. 이들 실험으로부터 일반식(I)의 화합물류는 중추신경계에 작용함을 알 수가 있다.The results of the pharmacological tests are summarized below. These experiments show that the compounds of formula (I) act on the central nervous system.

A. CRL 40,028(실시예 1) 독성에 관한 실험A. CRL 40,028 (Example 1) Toxicity Studies

위장내 투여할 때 생쥐의 LD50은 1,950mg/kg이다. 생쥐의 복강내에 256mg/kg, 512mg/kg 및 1,024mg/kg을 각각 투여할 때 사망율은 전혀 관찰되지 않았고, 생쥐의 복강내 투약에 대한 LD50은 2,048mg/kg이하 또는 이 정도에서 나타난다.When administered gastrointestinally, the LD 50 of the mouse is 1950 mg / kg. No mortality was observed when 256 mg / kg, 512 mg / kg and 1,024 mg / kg of mice were administered intraperitoneally, respectively, and LD 50 for intraperitoneal administration of mice appeared at or below 2,048 mg / kg.

위장내 투여에 대한 LD50이 복강내 투약에 대한 LD50에 접근한다는 사실은 투약된 복용량이 동물의 흥분을 일으키지 않으므로 더욱 용이하게 장의 벽에 견딤을 시사하여 준다.The fact that access to the LD 50 LD 50 for my medication administered intraperitoneally to my stomach because the medication dose to cause the excitement of the animals gives to suggest that endureth to the intestinal wall more easily.

아포모르핀과의 상호작용Interaction with Apomorphine

쥐 6마리의 무리에 아포모르핀 0.5mg/kg을 피하 주사한 후 CRL 40,028을 30분동안 투약하였다. 여기에서, CRL 40,028은 아포모르핀에 의해 유발되는 스테레오타입 행동에 대하여 아무런 작용도 나타내지않음을 발견하였다.Six rats were subcutaneously injected with apomorphine 0.5 mg / kg and then CRL 40,028 was administered for 30 minutes. Here, CRL 40,028 was found to show no action on the stereotype behavior induced by apomorphine.

이 후의 표 Ⅱ의 방법에 의해 얻어진 결과들을 표 Ⅲ에 나타냈다.The results obtained by the method of Table II thereafter are shown in Table III.

[표 3]TABLE 3

Figure kpo00013
Figure kpo00013

Figure kpo00014
Figure kpo00014

표 Ⅲ의 분석결과로부터 CRL 40,028은 30분 이내에서 나타나는 운동기능항진증을 일으키며, 1시간 후에 최대치에 도달하고, 4시간 이내에 사라짐을 알 수 있다.The analysis results of Table III show that CRL 40,028 causes motor dyskinesia within 30 minutes, reaches a maximum after 1 hour, and disappears within 4 hours.

사망율에 대한 효과Effect on mortality

1. 자발 운동성1. spontaneous motility

CRL 40,028은 16mg/kg의 투약량 이상에서 동물의 운동효과를 증가시킨다. 이 효과는 CRL 40,028의 효과의 대표적인 예이므로, 그의 운동을 더욱 정확하게 얻기 위한 시도를 행하였다. 투약당 12마리의 생쥐 무리나 대조용동물 24마리에 CRL 40,028을 점착성용액 및 생성물의 투약에 관한 표 Ⅲ의 식에 의하여 점착성 용액 64mg/kg의 투약량으로 사용하였다.CRL 40,028 increases the motor effects of animals at doses above 16 mg / kg. Since this effect is a representative example of the effect of CRL 40,028, an attempt was made to obtain its motion more accurately. CRL 40,028 was used as a dosage of 64 mg / kg of the adhesive solution according to the formula in Table III for the administration of the adhesive solution and the product to a group of 12 mice or 24 control animals per dose.

2. 잔존운동성2. Remaining Mobility

CRL 40,028의 자극효과는 자발 운동 효과가 방에 익숙해지는 동물에 의해 감소될 때에 더욱 명백해졌다.The stimulatory effects of CRL 40,028 became more apparent when the spontaneous motor effects were reduced by animals accustomed to the room.

3. 저산소증공격 후 운동 회복3. Exercise recovery after hypoxia attack

무산소증 후에 512,128 및 32mg/kg의 투약량에서 CRL 40,028을 투약한 생쥐는 대조동물의 경우보다 현저하게 큰 운동효과를 나타내었다.Mice dosed with CRL 40,028 at doses of 512,128 and 32 mg / kg after anoxia showed significantly greater motor effects than those of control animals.

상기에서 행한 실험결과로부터, CRL 40,028은 자극성 즉 동물정신약리학에 있어서 흥분 및 반응항진정및 운동 기능항진증을 갖는다.From the above experimental results, CRL 40,028 has irritation, that is, excitement and antiseptic calming and motor hyperactivity in animal psychopharmacology.

CRL 40,028이 암페타민형제 또는 정신자극제에 근사한가의 여부를 정하기 위하여, 암페타민과 카페인으로 비교실험을 행해 제4표에 기재하였다.To determine whether CRL 40,028 is close to amphetamine or mental stimulant, a comparative experiment was conducted with amphetamine and caffeine and listed in Table 4.

[표 4]TABLE 4

Figure kpo00015
Figure kpo00015

Figure kpo00016
Figure kpo00016

암페타민과의 상호작용Interaction with Amphetamine

CRL 40,028을 투약한 30분후에(쥐 6마리/복용량) 암페타민(2mg/kg)을 복강내로 주사하였다. CRL 40,028은 쥐에 있어서 암페타민에 의해 유발되는 스테레오타입 행동에 있어서 전체적인 변화를 일으키지 않으며, 이것은 암페타민의 작용의 효능을 촉진하지 않는다.Thirty minutes after administration of CRL 40,028 (6 mice / dose) amphetamine (2 mg / kg) was injected intraperitoneally. CRL 40,028 does not cause a global change in stereotype behavior induced by amphetamines in rats, which does not promote the efficacy of the action of amphetamines.

레세르핀과의 상호작용Interaction with Reserpin

6마리의 생쥐의 무리에 CRL 40,028을 투약하기 4시간전에 레세르핀(2.5mg/kg)을 복강내로 주사하였다.A group of six mice was injected intraperitoneally with reserpin (2.5 mg / kg) 4 hours prior to dose of CRL 40,028.

1. 온도에 대한 효과1. Effect on temperature

CRL 40,028의 256 및 64mg/kg에서 레세르핀의 이상고온효과가 부분적으로 저지된다.At 256 and 64 mg / kg of CRL 40,028 the hyperthermic effect of reserpine is partially arrested.

2. 하수증에 대한 효과2. Effect on sewage

CRL 40,028은 레세르핀에의해 생긴 안검(眼瞼) 하수증을 해소하지 못한다.CRL 40,028 does not resolve ptosis caused by reserpin.

옥소트레모린과의 상호작용Interaction with Oxoteremoline

생쥐(복용량당 6마리)에 CRL 40,028을 투약한 30분 후에 옥소트레모린 0.5mg/kg을 복강내로 투약하였다.Mice (6 per dose) were dosed intraperitoneally with 0.5 mg / kg of oxoteremoline 30 minutes after CRL 40,028.

1. 온도에 대한 효과1. Effect on temperature

특정복용량(256,16 및 4mg/kg, 그러나 64mg/kg, 이 아님)에서 CRL 40,028은 옥소트레모린의 이상고온효과가 적당히 저지된다.At certain doses (256, 16 and 4 mg / kg, but not 64 mg / kg), CRL 40,028 moderately inhibits the hypothermic effects of oxotremorin.

2. 전율에 대한 효과2. Effect on Tremor

CRL 40,028은 모든 복용량에서 옥소트레모린에 의해 야기되는 전율의 강도를 적당히 감소시킨다.CRL 40,028 moderately reduces the intensity of tremors caused by oxotremorin at all doses.

3. 말초코올린성장 후의 효과3. Effects after Peripheral Coolin Growth

CRL 40,028은 옥소트레모린에 의해 생기는 타액분비, 낙루(lachrymation) 및 배변(defaecation)에 있어서 증대현상을 변경하지 아니한다.CRL 40,028 does not alter augmentation in saliva secretion, lachrymation and defecation caused by oxotremorin.

4. 플레이트 테스트, 수축 및 전격에 대한 효과4. Effects on Plate Testing, Shrinkage and Lightning

CRL 40,028을 투여한 후, 30분후에 생쥐 20마리의 무리에 이 시험을 행하였다.Thirty mice after 30 minutes of administration of CRL 40,028 were subjected to this test.

높은 복용량(256 및 64mg/kg)에서 CRL 40,028은 고통을 수반하는 페스의 수효를 증가시켰다. 낮은 복용량(4.1mg/kg)에서 이와 같은 페스의 적당한 감소를 일으킴을 나타낸다. 무 복용시에 CRL 40,028은 운동성에 있어서 주요한 감소현상을 가져왔다. 높은 복용량(256mg/kg)에서만 전기충격의 경련효과에 대해 상대작용을 나타낸다.At high doses (256 and 64 mg / kg), CRL 40,028 increased the number of feces with pain. At low doses (4.1 mg / kg), this results in a moderate reduction of the feces. At no dose, CRL 40,028 resulted in a major decrease in motility. Only at high doses (256 mg / kg) it has a relative effect on the convulsive effect of the electric shock.

[표 2]TABLE 2

Figure kpo00017
Figure kpo00017

Figure kpo00018
Figure kpo00018

이들 비교시험 결과로부터 CRL 40,028은 다음과 같이 암페타민형 화합물과 다름이 나타났다.From these comparative tests, CRL 40,028 was different from the amphetamine type compound as follows.

스테레오타이피스의 부재.Absence of stereotypes.

아포모르핀 및 암페타민의 효과의 효능 촉진 부재.Absence of promoting efficacy of the effects of apomorphine and amphetamine.

레세르된에 대한 현저한 상쇄작용의 부재 및 생쥐무리에 있어서 특정 독성의 실질적 부재.Absence of significant trade-off for reserized and substantial absence of specific toxicity in mice.

그리하여, 다음과 같은 어떤 차이에도 불구하고, 카페인에 더 밀접한 정신자극제로 처리한다.Thus, despite any differences, they are treated with psychostimulants more closely to caffeine.

아포모르핀의 효과의 효능 촉진의 부재.Absence of promoting efficacy of the effect of apomorphine.

레세르핀에 의해 생기는 이상 고온에 대한 현저한 상쇄작용의 부재 및 전기충격 및 저산소의 효과의 악화의 부재.The absence of significant offsetting action against abnormal high temperatures caused by reserpin and the deterioration of the effects of electric shock and hypoxia.

B. 기타 생성물에 대한 시험B. Testing for Other Products

1) CRL 40,028(실시예 2)은 중추신경계에만 작용한다.1) CRL 40,028 (Example 2) acts only on the central nervous system.

이것은 산동효과(mydriatic effect) 부재에서, 옥소트레모린에 대해 상쇄작용을 갖는다. 이것은 암페타민형 화합물에 의해 생긴 스테레오타이피스를 촉진하며 생쥐의 접촉에 대해 반응항진성을 나타낸타.It has an offset against oxotremorin in the absence of a mydriatic effect. This promotes stereotypes caused by amphetamine-type compounds and shows hyperresponsiveness to mouse contact.

2) CRL 40,066(실시예 3)은 중추신경계에 대한 효과가 따라 카라기닌수종(carrageenin oedema)에 있어서 항-수종 효과를 나타낸다.2) CRL 40,066 (Example 3) shows an anti-edema effect on carrageenin oedema following its effect on the central nervous system.

3) CRL 40,221(실시예 4)는 트리사이클릭 항-억제제의 것과 근사한 정신약리적 스펙트럼, 즉3) CRL 40,221 (Example 4) is a psychopharmacological spectrum, ie, close to that of tricyclic anti-inhibitors, ie

항-레세르핀효과,Anti-reserpin effect,

항-옥스트레모린효과,Anti-oxtremorin effect,

암페타민형화합물에 의해 생긴 스테레오타이피스의 촉진(신진대사),Promotion of stereotypes caused by amphetamine-type compounds (metabolism),

전기충격에 의해 생기는 경련에 대한 보호,Protection against cramps caused by electric shock,

현저한 산동증(mydriasis)과 높은 복용량에서 이상고온Significant mydriasis and abnormal high temperatures at high doses

또한, 이것은 a) 상기 4. 플레이트테스트에서 어떤 효과(이미프라민)과 아미트리프탈린과 유사하나 노트리프탈린과는 유사하지 않음)과 b) 독성 복용량에 근접한 투약량에서 진정효과(이미 프라민과 노르트리프탈린과 유사하지만 아미트리프탈린과는 유사하지 않음)를 나타낸타. 최종적으로, 이것은 방에 익숙해진생쥐의 운동 효과를 재개시한다.In addition, it is characterized by: a) any effect in the plate test (imipramine) and similar to amitriphthalin but not similar to nophthalphthalin, and b) a sedative effect at a dose close to the toxic dose (already a pramin). And notriphthalin, but not amitriphthalin). Finally, this resumes the motor effect of mice accustomed to the room.

생쥐의 복강내로 투약한 CRL 40,221은 512mg/kg 이상의 LD-0을 나타낸다.CRL 40,221 dosed intraperitoneally of mice shows LD-0> 512 mg / kg.

4) CRL 40,222(실시예 5)는 중추신경계에 대해 작용하며 정신약리스팩트럼에서 다음과 같은 것은 발견되었다.4) CRL 40,222 (Example 5) acts on the central nervous system and found the following in the psychopharmaceutical spectrum.

암페타민에 의해 생긴 스테레오타이피스의 수명 연장,Extending the life of stereotypes caused by amphetamines,

옥소트레모린에 대한 적당한 작용,Moderate action on oxoteremoline,

항-레세르핀효과의 부재,Absence of anti-reserpin effect,

생쥐에 있어서 자발운동성의 증가(1mg/kg의 저투약량에서만)와 생쥐에 있어서 자극운동성의 자극(8mg/kg의 투약량에서).Increased spontaneous motility in mice (only at low doses of 1 mg / kg) and stimulation of stimulatory motility in mice (at dosages of 8 mg / kg).

생쥐에 복강내로 투약한 CRL 40,222는 128mg/kg 이상의 LD-0를 나타낸다.CRL 40,222 administered intraperitoneally to mice shows LD-0> 128 mg / kg.

5) CRL 40,260(실시예 6)은 저독성(그의 LD-0는 생쥐에 있어서 복강내 투약에 대해 1,024mg/kg이상임)의 물질이며, 정신 요법분야에 있어서, 동물들에 있어서 다음과 같은 효과를 발생시킨다.5) CRL 40,260 (Example 6) is a low toxicity substance whose LD-0 is greater than 1,024 mg / kg for intraperitoneal dosing in mice and has the following effects in animals in the field of psychotherapy: Generate.

생쥐 및 쥐에 있어서 저운동성으로 안정,Low motility in mice and rats,

생쥐에 있어서 자발운동성의 저하 및 생쥐와 쥐에 있어서 반응 항진성의 저하.Decrease in spontaneous motility in mice and hyperresponsiveness in mice and rats.

6) CRL 40,261(실시예 7)은 그의 정신약리스팩트럼에 있어서 다음과 같은 효과를 나타낸다.6) CRL 40,261 (Example 7) has the following effects on its psychopharmaceutical spectrum.

생쥐에 있어서 암페타민에 의해 생긴 스테레오타이피스의 수명연장,Life extension of amphetamine-induced stereotypes in mice,

레세르핀에 기인한 이상 고온의 상응(레세르핀에 의해 유발된 안검하수증을 변경시키지 않고),Abnormally high temperature correspondence due to reserpin (without altering ptosis caused by reserpin),

옥소트레모린에 대한 적당한 효과 및Moderate effect on oxoteremoline and

생쥐에 있어서 자발운동성의 증가(2mg/kg, 8mg/kg 및 32mg/kg의 투약량에서).Increased spontaneous motility in mice (at dosages of 2 mg / kg, 8 mg / kg and 32 mg / kg).

생쥐에 복강내로 투약한 CRL 40,261의 LD-0는 256mg/kg 이상이었다.LD-0 of CRL 40,261 administered intraperitoneally to mice was greater than 256 mg / kg.

7) CRL 40,277(실시예 8)은 중추신경계에 작용한다. 그의 정신약리스펙트럼에서 다음과 같은 것들이 발견되었다.7) CRL 40,277 (Example 8) acts on the central nervous system. In his psychopharmaceutical spectrum, the following were found:

첫째로, 고투약량에서 다음과 같은 효과들:First, the following effects at high doses:

이상고온, 저운동성, 레세르핀 및 옥소트레모린의 이상 고온효과의 악화, 전기충격의 치명효과의 악화와, 둘째로, 중간 투약량에서, 현존하는 자극을 더 유발시키나 항시 중간강도인 형태의 효과들:Abnormal high temperature, low motility, exacerbation of abnormal high temperature effects of reserpin and oxotremorin, deterioration of lethal effects of electric shock, and, secondly, at moderate dosages, more stimulating extant stimuli but at moderate intensity. field:

반응항진성, 암페타민의 효과의 효능촉진 및 일정치 않은 잔류 저 운동성.Hyperresponsiveness, promoting efficacy of the effects of amphetamines and inconsistent residual low motility.

생쥐에 대한 복강내 투약에 대해서, CRL 40,277의 LD-0는 512mg/kg 이상이다.For intraperitoneal dosing in mice, the LD-0 of CRL 40,277 is at least 512 mg / kg.

8) CRL 40,278(실시예 9)은 중추신경제에 작용한다. 생쥐의 복강내 투약에 대해서, 그의 LD-0는1,024mg/kg 이상이다.8) CRL 40,278 (Example 9) acts on the central economy. For intraperitoneal administration of mice, its LD-0 is at least 1,024 mg / kg.

Claims (1)

하기 일반식(Ⅱ)의 술피드를 과산화수소로 산화시키고, R'기를 R기로 전환시킴을 특징으로 하는 하기 일반식(I)의 벤즈히드릴술포닐 화합물 및 그 염의 제조 방법.A method for producing a benzhydrylsulfonyl compound of the following general formula (I) and a salt thereof, wherein the sulfide of the general formula (II) is oxidized with hydrogen peroxide and the R 'group is converted to an R group.
Figure kpo00019
Figure kpo00019
상기식에서,In the above formula, n은 1,2 또는 3을 나타내고,n represents 1,2 or 3, R은
Figure kpo00020
또는 2-△2-이미다졸리닐을 나타내며,
R is
Figure kpo00020
Or 2-Δ 2 -imidazolinyl,
R'는 R과 같거나 R로 전환될 수 있는 기를 나타낸다.R 'is the same as R or represents a group that can be converted to R.
KR7602469A 1976-10-02 1976-10-02 Process of preparing benzhydrysulphinyl derivatives KR800000144B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR7602469A KR800000144B1 (en) 1976-10-02 1976-10-02 Process of preparing benzhydrysulphinyl derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR7602469A KR800000144B1 (en) 1976-10-02 1976-10-02 Process of preparing benzhydrysulphinyl derivatives

Publications (1)

Publication Number Publication Date
KR800000144B1 true KR800000144B1 (en) 1980-03-09

Family

ID=19202764

Family Applications (1)

Application Number Title Priority Date Filing Date
KR7602469A KR800000144B1 (en) 1976-10-02 1976-10-02 Process of preparing benzhydrysulphinyl derivatives

Country Status (1)

Country Link
KR (1) KR800000144B1 (en)

Similar Documents

Publication Publication Date Title
US4066686A (en) New benzhydrysulphinyl derivatives
US6255307B1 (en) Pyrazine compounds
US4098824A (en) Benzhydrylsulphinyl derivatives
AU3108097A (en) 4-phenylpiperidine compounds
IE44416B1 (en) Substituted phenyl amidines
SU728713A3 (en) Method of preparing salicylanilide derivatives
BG60835B2 (en) Epininester, method for its preparation and medicamentous compounds
FR2493315A1 (en) PIPERAZINE DERIVATIVE, PROCESS FOR PREPARATION AND ANALGESIC COMPOSITION CONTAINING THE SAME
US3801636A (en) 3,4,5-tri-substituted cinnamides
WO2014172363A2 (en) Combretastatin analogs
KR800000144B1 (en) Process of preparing benzhydrysulphinyl derivatives
US3574203A (en) 2-substituted 5,6-dihydro-4h-1,3-thiazines
US3989722A (en) 1-Aminomethyl-2,2-diaryl-cyclopropane carboxamides
EP0157399B1 (en) 4-(5H-Dibenzo[a,d]cyclohepten-5-yl) piperidine compounds
JPH0135822B2 (en)
US4367239A (en) Nitrosourea derivatives, pharmaceutical compositions thereof and method of preparation
JPH0471067B2 (en)
EP0026989B1 (en) Nitrosourea derivatives, process for preparing them, and pharmaceutical compositions containing them
US3972931A (en) N,N'-Disubstituted benzamidines
JPS6112900B2 (en)
US4353923A (en) Pharmaceutical composition containing a benzofurancarboxamide derivative as the active ingredient
HU184791B (en) Process for preparing derivatives of tetrahydro-pyrid-4-yl-indole
CA1138868A (en) Quinoxaline-di-n-oxide derivatives
US3452030A (en) 4-(n-isobutyrylanilino)-1-benzylpiperidine
CA1079275A (en) Benzhydrylsulphinyl derivatives